SEC Contract Filing

Filing Date: 2021-03-23

Document Content:
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>5
<FILENAME>ubx-ex1018_236.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ubx-ex1018_236.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIRST AMENDMENT TO COMPOUND LIBRARY AND OPTION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment (the &#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;), dated as of March 28, 2018 (the <font style="text-decoration:underline;">Amendment Effective Date</font>&#8221;) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (&#8220;<font style="text-decoration:underline;">Ascentage</font>&#8221;), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (&#8220;<font style="text-decoration:underline;">Unity</font>&#8221;), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002.&nbsp;&nbsp;Ascentage and Unity are sometimes referred to herein as individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties&#8221;.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">A.</font><font style="font-family:Calibri;font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties entered into a Compound Library and Option Agreement (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Library Agreement</font><font style="color:#000000;">&#8221;) dated February 2, 2016 (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Original Effective Date</font><font style="color:#000000;">&#8221;), which granted Unity the right to screen Ascentage&#8217;s collection of BCL-2/BCL-xL inhibitor compounds as well as additional BCL-2/BCL-xL inhibitor compounds discovered by Ascentage during the term of the Library Agreement, including pursuant to that certain Research Services Agreement between the Parties dated February 2, 2016 (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">BCL Compounds</font><font style="color:#000000;">&#8221;) to identify compounds with potential utility in the treatment of age-related conditions other than Oncology Indications. Defined terms used herein and not otherwise defined shall have the meanings ascribed in the Library Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">B.</font><font style="font-family:Calibri;font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> On the Original Effective Date the Parties also entered that certain APG1252 License Agreement (the &#8220;</font><font style="text-decoration:underline;color:#000000;">1252 License Agreement</font><font style="color:#000000;">&#8221;) pursuant to which Ascentage granted Unity exclusive rights to a BCL Compound known as APG-1252 for the prophylaxis and treatment of, and palliation of symptoms associated with, age related indications other than Oncology Indications.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">C.</font><font style="font-family:Calibri;font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ascentage is also a party to a License Agreement with the Regents of the University of Michigan (&#8220;</font><font style="text-decoration:underline;color:#000000;">Michigan</font><font style="color:#000000;">&#8221;) dated December 1, 2010 (as amended on May 30, 2013, February 2, 2016, May 10, 2017 and June 1, 2017, the &#8220;</font><font st